Zydus Lifesciences Ltd (ZYDUSLIFE)
₹1,156.90
Mkt cap
₹1.12L Cr
P/E ratio
23.00
P/B
4.30
Div yield
0.09%
ROE
21.20%
ROCE
21.10%
EPS (TTM)
₹50.30
Book value
₹269
52W range
861–1,205
Sector
Healthcare
Price history
Previous close
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
NSE ZYDUSLIFEBSE 532321
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−3.99% from high₹1,157
₹861+34.43% from low₹1,205
Current
₹1,156.90
Prev close
₹1,120.00
Day
+3.29%
Price performance
1D
+3.29%
1W
−0.38%
1M
+3.83%
3M
+4.64%
6M
+28.99%
1Y
+16.73%
YTD
+26.18%
Financials
Revenue, profit & margin
P/E ratio
23.0×
ZYDUSLIFE is 32% below the sector median of 34.0×
ZYDUSLIFE23.0×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,140 | 4,369 | 4,505 | 5,534 | 6,208 | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 | |
| Expenses | 3,634 | 3,223 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,402 | 4,485 | 4,107 | 5,048 | 5,033 | 6,088 | |
| Operating Profit | 1,505 | 1,146 | 1,102 | 1,630 | 2,084 | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 | 1,929 | |
| OPM % | 29% | 26% | 24% | 29% | 34% | 28% | 26% | 33% | 32% | 33% | 26% | 34% | 24% | |
| Other Income | 21 | 53 | 60 | 160 | 63 | 68 | 57 | -139 | 155 | 75 | 26 | -263 | 88 | |
| Interest | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 | 123 | 156 | |
| Depreciation | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 555 | |
| Profit before tax | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 | |
| Tax % | 16% | 22% | 23% | 21% | 23% | 29% | 15% | 25% | 23% | 27% | 29% | 19% | 27% | |
| Net Profit | 1,134 | 803 | 790 | 1,246 | 1,482 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 | |
| EPS in Rs | 10.74 | 7.91 | 7.80 | 11.75 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.42 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.29% · closed higher next day 29 of last 61
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 7 Nov '23◦ | 9 Feb '24◦ | 17 May '24◦ | 9 Aug '24◦ | 12 Nov '24◦ | 5 Feb '25◦ | 20 May '25◦ | 12 Aug '25 | 6 Nov '25 | 9 Feb '26 | 19 May '26 | 11 Aug '26 |
| Earnings day | +4.67% | +6.41% | +5.00% | −3.88% | +1.47% | +3.19% | +0.72% | +0.01% | −3.60% | +3.97% | +2.80% | +1.18% |
| +1 day | +2.54% | +6.55% | +3.51% | −9.64% | +0.81% | +1.76% | +2.28% | +3.46% | −2.84% | −0.10% | +5.02% | −1.99% |
| +5 days | +5.78% | +12.73% | +0.68% | −8.32% | −0.07% | −3.50% | +4.79% | +2.90% | −2.84% | +2.51% | +8.87% | −7.26% |
| +15 days | +7.10% | +17.54% | +3.30% | −14.37% | +4.77% | −10.28% | +10.81% | +5.90% | −3.55% | +2.11% | +10.82% | −3.09% |
| +30 days | +13.84% | +24.18% | +2.21% | −19.17% | +0.76% | −5.46% | +12.69% | +6.67% | −5.97% | −0.20% | +10.97% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Re 1 Per Share | — | 24 Jul '26 | 24 Jul '26 |
| other Buy Back | — | 29 May '26 | 29 May '26 |
Shareholding
as of Jun 202675.02%Promoter
Promoters75.02%0.02
FIIs6.89%0.06
DIIs11.27%0.07
Public6.83%0.03
Government0.00%
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts84
TranscriptAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025PPTMay 2025TranscriptMar 2025PPTMar 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024
Credit ratings6
Announcements5
Settlement Agreement 5 Sep - Zydus USA settled indirect reseller litigation for USD 5.9 million on September 5, 2026.Transcript Of The 31St Annual General Meeting 1 Sep - Transcript of Aug. 11, 2026 AGM notes Rs 1,100 crore buyback, FY26 results, dividend, and key reappointments.Announcement under Regulation 30 (LODR)-Press Release / Media Release 31 Aug - EVIDENCES-X Phase II(b) Saroglitazar Mg trial in MASH met primary endpoint with positive topline results.Incorporation Of A Wholly Owned Subsidiary In Gift City, Gandhinagar, Gujarat 26 Aug - Zydus incorporated wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in GIFT City on August 25, 2026.ESG Rating 25 Aug - CRISIL assigned Zydus Lifesciences ESG score 66, up from 61, for FY2025-26.